47 results about "Methylcobalamin" patented technology

Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that reduce the production of homocysteine and either re-methylate homocysteine back to S-adenosylmethionine, or facilitate its conversion downstream to cystathione. The method of the invention may be achieved by administering 5-methyl tetrahydrofolate, methylcobalamin, and one or more compounds selected from the group consisting of betaine, pyridoxal-5-phosphate, N-acetyl-cysteine, and other cofactors.

A method of treating a disorder by nasally administering methylcobalamin, with or without folinic acid. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dislexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel.

A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. A lollipop for treating a psychological or neuro-physiological disorder and method of making thereof.

The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition containing mecobalamin and a preparation method thereof. The pharmaceutical composition containing mecobalamin is composed of, by mass percentage, 0.01-1% of methylcobalamin, 1%-10% of a stabilizer, 40-95% of a diluent, 0-20% of a disintegrant, and 0.1-10% of a lubricant. The preparation method consists of: premixing mecobalamine and part of the diluents, then mixing the pre-mixture with the stabilizer, the diluent and the disintegrant to obtain mixed powder, mixing the mixed powder with the lubricant for a certain period of time to obtain mixed raw material powder, and subjecting the mixed raw material powder to direct tabletting and coating. The method provided by the invention adopts a dry granulation process, involves fewer steps, avoids the influence of moisture and heat to the main drug, further improves the quality of mecobalamin tablets, lowers the cost, and is beneficial to industrial production.

A process for treating psoriasis and similar skin disorders whereby two formulations are used. The first formulation in a cream, gel, lotion, foam or ointment base is used two or more times daily, and contains effective amounts of (but not limited to) methylcobalamin, niacinamide, select cetylated fatty esters, and antioxidants. This formulation is used to suppress immunoproliferative and inflammatory mediated activities that play significant roles in hyperproliferation and erythema. The second formulation, used selectively to reduce plaque thickening and to reduce irritation, contains effective amounts of (but not limited to) salicylic acid and select cetylated fatty esters in a cream, gel, lotion or ointment base, with pH optimized for exfoliation properties. The unique combination of salicylic acid (or other β- or α-hydroxy acid) and cetylated fatty esters provides keratolytic activity while suppressing irritation and inflammation. The invention for this novel two-step polytherapy, are disclosed including the mode of sequential administration.

The present invention provides a freeze-dried preparation containing a high content of methylcobalamin which is highly stable over time and can be used in high-concentration methylcobalamin therapy. Disclosed is the freeze-dried preparation containing methylcobalamin or a pharmacologically acceptable salt thereof and an excipient wherein the excipient is at least in an amorphous state. The freeze-dried preparation according to the present invention is characterized in that when the excipient comprises a sugar and a sugar alcohol, the excipient in the amorphous state is contained in an amount of at least 20% by weight, based on the total weight of the sugar and the sugar alcohol.

A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxidation therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.

The present invention relates to a method for purification and/or concentration of natural cobalamins by adsorption on insoluble materials containing carboxylic groups. Especially the method comprises providing a first solution comprising at least one type of natural cobalamins, providing an adsorbent material comprising carboxylic groups capable of making specific interaction with said natural cobalamins, contacting said first solution comprising at least one type of natural cobalamins with said adsorbent material, whereby at least a part of said at least one type of natural cobalamins becomes adsorbed and/or bound to said adsorbent material, and elution of said at least one type of natural cobalamins from said adsorbent material, hereby obtaining a concentrated solution comprising at least one cobalamin. The natural cobalamins can be one or more of the natural cobalamins 5'-deoxy-5'-adenosyl-Cobalamin (adenosyl- Cbl, Ado Cbl), methyl-cobalamin (methyl-Cbl, Me Cbl) and aquo-cobalamin (aquo-Cbl, H2O Cbl).

The present invention describes bioactive vitamin combinations that can be used in combination with other bioactive compounds, such as active drug ingredients or active vaccine components, to increase their therapeutic effects. The bioactive vitamin combinations comprise therapeutically effective amounts of L-Methylfolate, Adenosylcobalamin and Methylcobalamin.

Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed.

The present invention relates to an intranasal composition, particularly once weekly intranasal composition comprising methylcobalamin and at least one gelling agent and a process for preparation thereof.

The invention relates to a light reaction device and applications in preparation of hydroxycobalamin or salts thereof. The light reaction device comprises a light reaction device, a circulating pump, a mixing and stirring device and an air filter. The light reaction device is composed of a housing box, a strong light, a reaction tank and an aerated pipe. The side walls of the box body of the housing box are wallboards with porous structures. Diffuse reflection plates are arranged at the inner sides of the side walls. The strong light is arranged on the box cover. The reaction tank is arranged at the bottom of the housing box. The aerated pipe is arranged inside the reaction tank and immersed in reactive substances. Through the light reaction device, the reaction conversion rates of methylcobalamin and cobamamide in an aqueous solution reach above 99%, the chromatographic purity of the generated hydroxycobalamin reaches above 98%, the product yield reaches above 98%, and the production efficiency is raised by above 5 times compared with that of a normal reactor.

Vitamin B-12 deficiency is very common among population. The main causes of B- 12 deficiency include lack of intrinsic factors and other intestinal factors (e.g. malabsorption), rare genetic disorders, and inadequate intake. The present invention relates to intranasal formulations of vitamin B derivatives such as methylcobalamin, Cyanocobalamin which provide enhanced transnasal absorption.

A formulation and method for treating or preventing a deficiency of certain nutrients in patients undergoing a therapy in which one or more proton pump inhibitors is administered. The formulation includes:

The formulation may also include 10-50 mg of a proton pump inhibitor.

A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of: a mixture of human plasma composed of pluripotent adult stem cells comprising very small embryonic like stem cells from autologous plasma or allogeneic plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxygen therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), additional PRP pluripotent adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.